Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis (625)

Kristen Krysko, Jennifer Graves, Mary Rensel, Bianca Weinstock-Guttman, Alice Rutatangwa, Gregory Aaen, Anita Belman, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu Goyal, Yolanda Harris, Lauren Krupp, Timothy Lotze, Soe Mar, Manikum Moodley, Jayne Ness, Moses Rodriguez, John Rose, Teri Schreiner, Jan-Mendelt Tillema, Michael Waltz, T. Charles Casper, Emmanuelle Waubant
First published April 14, 2020,
Kristen Krysko
1Neurology, University of California San Francisco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Graves
2Neurology, University of California San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Rensel
3Neurology, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bianca Weinstock-Guttman
4Neurology, State University of New York at Buffalo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Rutatangwa
1Neurology, University of California San Francisco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Aaen
5Pediatrics, Loma Linda University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Belman
6Neurology, New York University Langone Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Benson
7Neurology, Boston Children’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanuja Chitnis
8Pediatric Neurology, Massachusetts General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Gorman
7Neurology, Boston Children’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manu Goyal
9Mallinckrodt Institute of Radiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yolanda Harris
11Nursing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Krupp
6Neurology, New York University Langone Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Lotze
13Neurology, Texas Children’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soe Mar
10Neurology, Washington University in Saint Louis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manikum Moodley
3Neurology, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jayne Ness
12Pediatrics, University of Alabama at Birmingham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moses Rodriguez
14Neurology, Mayo Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Rose
15Neurology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teri Schreiner
17Neurology & Pediatrics, University of Colorado
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan-Mendelt Tillema
14Neurology, Mayo Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Waltz
16Pediatrics, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Charles Casper
16Pediatrics, University of Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuelle Waubant
1Neurology, University of California San Francisco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis (625)
Kristen Krysko, Jennifer Graves, Mary Rensel, Bianca Weinstock-Guttman, Alice Rutatangwa, Gregory Aaen, Anita Belman, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu Goyal, Yolanda Harris, Lauren Krupp, Timothy Lotze, Soe Mar, Manikum Moodley, Jayne Ness, Moses Rodriguez, John Rose, Teri Schreiner, Jan-Mendelt Tillema, Michael Waltz, T. Charles Casper, Emmanuelle Waubant
Neurology Apr 2020, 94 (15 Supplement) 625;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: We assessed real-world effectiveness of initial treatment with newer compared to injectable disease-modifying therapies (DMT) on disease activity in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS).

Background: Treatment of pediatric MS is challenging as most DMTs lack randomized controlled trial data in children.

Design/Methods: This is a cohort study of children with MS/CIS followed at 12 clinics in the US Network of Pediatric MS Centers, who received initial therapy with newer (fingolimod, dimethyl fumarate, teriflunomide, natalizumab, rituximab, ocrelizumab) or injectable (interferon-beta or glatiramer acetate) DMTs. Propensity scores (PS) were computed with logistic regression to predict newer DMT use, including preidentified confounders. Relapse rate while on initial DMT was modeled with negative binomial regression, adjusted for PS-quintile. Time to new/enlarging T2 hyperintense and gadolinium-enhancing lesions on MRI brain were modeled with midpoint survival analyses, adjusted for PS-quintile.

Results: 741 children (66% female, 15% CIS) began therapy before 18 years, 197 with newer and 544 with injectable DMTs. Those started on newer DMTs were older (15.2 vs. injectable 14.4 years, p=0.001) and less likely to have a monofocal presentation (37% vs. injectable 55%, p<0.001). In PS-quintile adjusted analysis, those started on newer DMTs had lower relapse rate than those on injectables (rate ratio 0.45, 95% CI 0.29–0.70, p<0.001; rate difference 0.27, 95% CI 0.14–0.40, p=0.004). One would need to treat with newer over injectable DMTs for 3.7 person-years to prevent one relapse. Those started on newer DMTs also had lower rate of new/enlarging T2 (HR 0.51, 95% CI 0.36–0.72, p<0.001) and gadolinium-enhancing lesions (HR 0.38, 95% CI 0.23–0.63, p<0.001) than those on injectables.

Conclusions: Initial treatment of pediatric MS/CIS with newer DMTs led to better disease activity control compared to injectables, supporting greater effectiveness of newer therapies. Long-term safety data for newer DMTs is required.

Disclosure: Dr. Krysko has received research support from MS fellowship grant from NMSS; MS fellowship grant from Biogen.Dr. Graves has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Novartis, and Celgene. Dr. Graves has received research support from the National MS Society, Race to Erase MS, UCSF CTSI RAP Program, Biogen, and Genentech.Dr. Rensel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advisory Board or panel: Serono, Biogen. Consultant: Biogen, Teva, Genzyme and Novartis. Speaker’s Bureau: Novartis, Genzyme, Biogen, Multiple Sclerosis Association of America.. Dr. Rensel has received research support from Grants/Research support: She has received commercial research support from Medimmune, Novartis, Biogen (MS Paths) and Genentech. She has received foundation/society research support from the National Multiple Sclerosis Society. She has received educationa. Dr. Weinstock-Guttman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, , Novartis, Genentech, EMD Serono, Abbvie, Mallickrodt, Bristol Myers.. Dr. Weinstock-Guttman has received research support from Biogen, Novartis, Genentech, and EMD Serono..Dr. Rutatangwa has received research support from She is supported by a Biogen MS fellowship grant..Dr. Aaen has received research support from Biogen.Dr. Belman has nothing to disclose. Dr. Benson has received research support from She has received funding for research unrelated to this work for a Biogen sponsored clinical trial..Dr. Chitnis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Sanofi-Genzyme, Roche, and Genentech. Dr. Chitnis has received research support from Novartis, Octave Biosciences, Mallinckrodt, and Verily Life Sciences.Dr. Gorman has received research support from He has participated in clinical trials funded by Novartis and Biogen, and received research funding from Pfizer..Dr. Goyal holds stock and/or stock options in IBM Stock.Dr. Harris has nothing to disclose. Dr. Krupp has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Everyday Health, Gerson Lehman, Novartis, RedHill Biopharma, Roche, Shire, and Sanofi-Aventis. Dr. Krupp has received royalty, license fees, or contractual rights payments from Biogen, Reata Pharma, AbbVie Pharmaceuticals, Amicus Therapeutics, SA Inventions, Finkhar Health, Janssen Pharmaceuticals, Eisai, IPSOS, Octapharma, Atara Biotherapeutics, Merck, Research Tech, and ERT Inc. Dr. Krupp has received research support from Biogen and Novartis.Dr. Lotze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with He has served as a consultant/speaker for Biogen.. Dr. Lotze has received research support from PTC Therapeutics, Serepta Therapeutics and Catalyst Therapeutics. Dr. Mar has nothing to disclose. Dr. Moodley has nothing to disclose. Dr. Ness has received research support from Chugai-Roche.. Dr. Rodriguez has nothing to disclose. Dr. Rose has received research support from AbbVie, Biogen, Teva, the Cumming Foundation, the National Institutes of Health, the National Multiple Sclerosis Society, and the US Department of Veterans Affairs. Dr. Schreiner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with ACI. Dr. Schreiner has received research support from ADAMAS. Dr. Tillema has received research support from He has received grant support from NIH and the NMSS.. Dr. Waltz has nothing to disclose. Dr. Casper has nothing to disclose. Dr. Waubant has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EW has not received any pharmaceutical company honorarium. She is site PI for Novartis and Roche multicenter trials. She volunteers on an advisory board for a Novartis trial. She is a non-remunerated advisor for clinical trial design to Novartis, Biogen-I. Dr. Waubant has received research support from She has funding from the NMSS, PCORI and the Race to Erase MS. She receives compensation as the section editor for Annals of Clinical and Translational Neurology, and co-Chief editor for MSARD.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise